Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat once-daily versus twice-daily crossover study in COPD
2008-006305-16Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: 24-hour FEV1 area under the curve after 14 days. Started Dec 2008; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-006305-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006305-16.